1. Life Sciences Litigation Matters We Handle
Patent, product liability, FCA, licensing, and trade secret disputes each turn on a different record, so the first task is to identify what must actually be proved. The product lifecycle, governing agreements, regulatory history, and location of technical evidence can materially change how the litigation develops.
Patent and Intellectual Property Litigation
Patent disputes can affect a product before launch, during regulatory review, or after commercialization. Matters may involve infringement, validity, claim construction, prior art, damages, or competition involving branded, generic, and biological products.
The Hatch-Waxman framework creates a specialized form of pharmaceutical patent litigation involving generic ANDA and certain 505(b)(2) drug applications because specified regulatory submissions can constitute an act of infringement under 35 U.S.C. § 271(e)(2). Biosimilar patent disputes arise under a separate statutory framework created by the Biologics Price Competition and Innovation Act. The FDA's BPCIA materials describe the abbreviated pathway for biosimilar and interchangeable biological products.
Patent analysis can require review of claims, prior art, formulations, manufacturing processes, product specifications, laboratory records, regulatory submissions, and expert opinions. Related intellectual property litigation may also involve trade secrets, proprietary technology, or brand rights connected to the same product.
Trade Secret and Proprietary Technology Disputes
A formula, assay design, manufacturing method, development dataset, laboratory process, or commercialization plan may represent substantial competitive value long before a product reaches market.
A trade secret dispute often turns on whether the information qualified for protection and whether it was improperly acquired, disclosed, or used. Access permissions, confidentiality agreements, laboratory systems, download histories, device forensics, communications, and evidence of internal safeguards can become central.
When confidential research or technology allegedly moves to a former employee, collaborator, or competitor, trade secret litigation may require immediate evidence preservation, forensic review, and evaluation of injunctive relief.
Licensing and Commercial Disputes
A licensing dispute may appear to be a contract case but hinge on whether a clinical, technical, or regulatory milestone actually occurred.
Life sciences agreements commonly allocate technology rights, development obligations, regulatory responsibilities, milestone payments, royalties, manufacturing duties, or commercialization territories. Disputes may concern:
Patent or technology licenses
Research and development agreements
Collaboration agreements
Milestone and royalty payments
Supply and manufacturing contracts
Commercialization rights
Termination provisions
Ownership of jointly developed technology
The controlling record can therefore extend beyond the contract itself to development files, regulatory submissions, product data, correspondence, and royalty calculations.
Product Liability and Mass Tort Litigation
Product liability cases involving pharmaceuticals, biologics, or medical devices can turn on alleged defects, warnings, manufacturing issues, adverse events, or causal relationships between a product and claimed injury.
Clinical studies, labeling history, post-market safety data, adverse-event information, manufacturing records, scientific literature, regulatory communications, and expert testimony can all shape the causation and warning analysis.
Where similar claims are filed by numerous plaintiffs, the litigation may involve multidistrict proceedings, coordinated discovery, bellwether cases, or broader settlement strategy. Liability standards can still vary by state even when the product and scientific record are national in scope.
False Claims Act and Government Investigations
Claims data and reimbursement records often matter more than broad compliance policies once an FCA investigation begins.
Life sciences companies may face federal investigations involving medical necessity, sales practices, pricing, patient assistance, kickbacks, or representations connected to federally funded healthcare programs. In September 2026, DOJ announced a $32 million resolution involving allegations that a pharmaceutical company funded Medicare beneficiary copayments through patient assistance foundations. In July 2026, Labcorp agreed to pay $14.5 million to resolve allegations involving medically unnecessary urine drug testing billed to Medicare.
The DOJ Dompé resolution and DOJ Labcorp resolution illustrate continued enforcement involving pharmaceutical and laboratory practices.
An FCA matter can require claims data, sales and marketing communications, compliance records, reimbursement information, contracts, medical-necessity documentation, and government correspondence. A related False Claims Act defense may also require analysis of scienter, materiality, qui tam allegations, and potential damages.
Antitrust and Competition Disputes
Patent rights, market entry, licensing, pricing, and distribution arrangements can create competition issues separate from the underlying IP or contract dispute.
The record may involve market definition, product substitution, exclusivity provisions, patent settlements, competitor conduct, or allegations that a commercialization strategy restricted competition. Antitrust analysis should remain distinct from patent or contract analysis even when all three concern the same product.
2. Why Life Sciences Litigation Requires Industry-Specific Analysis
A patent claim may turn on molecular structure or manufacturing data, while a product case may turn on clinical evidence, labeling history, and causation. FDA records can become central in yet another way when enforcement, manufacturing, labeling, or regulatory conduct is disputed.
Scientific and Technical Evidence
A scientific conclusion is useful in litigation only if it answers the legal question before the court.
The record often includes:
Laboratory and development records
Clinical study data
Analytical testing
Manufacturing information
Adverse-event records
Epidemiological evidence
Technical specifications
Expert methodology
Causation analysis
Expert opinions must be grounded in the relevant factual record and satisfy the evidentiary standard applied by the court. A technically sophisticated opinion that does not address the disputed legal element may have limited value.
FDA and Regulatory History
FDA inspection and compliance records can become relevant in litigation involving manufacturing, product quality, labeling, promotion, or regulatory conduct.
The FDA Investigations Operations Manual addresses agency inspections, investigations, evidence development, and regulatory activities. Records generated through those processes may later matter in product liability, enforcement, contract, or other litigation.
The significance of a regulatory document depends on why it is being offered. Labeling history can bear on a warning issue, while FDA correspondence may matter to a dispute over a regulatory milestone or alleged compliance representation.
Intellectual Property and Commercialization
The legal issues can change as a product moves from invention to market:
Patent protection → research and development → regulatory review → licensing → commercialization → litigation.
A patent ruling may affect market entry. A licensing dispute may depend on regulatory approval or a development milestone. Trade secret claims can arise from the same collaboration that produced jointly developed technology.
Mapping the disputed event to the product lifecycle helps identify the commercial consequence of the relief being sought.
3. How the Type of Dispute Changes the Litigation Strategy
A patent case can rise or fall on claim construction and prior art, while an FCA matter may depend on claims data, materiality, and scienter. A single discovery template is therefore unlikely to capture the evidence that matters across both disputes.
| Dispute | Central Question | Important Evidence |
|---|---|---|
| Patent | Are enforceable patent rights infringed, or are the asserted claims invalid? | Patent claims, prior art, technical data |
| Trade Secret | Was protected information improperly acquired, disclosed, or used? | Access controls, confidentiality records, communications, forensics |
| Licensing | What rights, milestones, and payment obligations govern the parties? | Agreements, amendments, development records, royalty data |
| Product Liability | Did the product allegedly cause the claimed injury under applicable law? | Clinical data, labeling, scientific literature, regulatory and expert evidence |
| FCA / Enforcement | Were claims or representations false or fraudulent, material, and made with the required state of mind? | Claims data, compliance records, internal communications, government correspondence |
| Commercial | Did a party fail to perform a contractual or business obligation? | Contracts, notices, transaction records, correspondence |
Patent
- Central QuestionAre enforceable patent rights infringed, or are the asserted claims invalid?
- Important EvidencePatent claims, prior art, technical data
Trade Secret
- Central QuestionWas protected information improperly acquired, disclosed, or used?
- Important EvidenceAccess controls, confidentiality records, communications, forensics
Licensing
- Central QuestionWhat rights, milestones, and payment obligations govern the parties?
- Important EvidenceAgreements, amendments, development records, royalty data
Product Liability
- Central QuestionDid the product allegedly cause the claimed injury under applicable law?
- Important EvidenceClinical data, labeling, scientific literature, regulatory and expert evidence
FCA / Enforcement
- Central QuestionWere claims or representations false or fraudulent, material, and made with the required state of mind?
- Important EvidenceClaims data, compliance records, internal communications, government correspondence
Commercial
- Central QuestionDid a party fail to perform a contractual or business obligation?
- Important EvidenceContracts, notices, transaction records, correspondence
The table also helps identify which witnesses, experts, regulatory records, and preservation steps should receive priority.
4. How Life Sciences Litigation Typically Develops
Early case planning should separate the legal claim from the technical record, regulatory exposure, and business consequences that may affect how the case proceeds.
Early Case and Risk Assessment
Initial review should identify the claims and defenses, jurisdiction, deadlines, product or technology involved, potential injunctive exposure, regulatory involvement, and related litigation or investigations.
Patent and FCA disputes commonly involve federal law. Product liability, licensing, and commercial claims can involve state substantive law, federal jurisdiction, or both depending on the claims and parties.
Preserve Scientific, Regulatory, and Commercial Evidence
Laboratory notebooks, electronic research systems, validation data, clinical records, source code, specifications, regulatory correspondence, collaboration files, contracts, internal messaging, and executive communications can all become discovery sources.
Preservation also requires identifying the people who understand those records. Scientists, engineers, regulatory personnel, commercial teams, and outside consultants may become important fact or expert witnesses.
Expert and Technical Analysis
The expert should match the disputed issue, not merely the industry.
Patent litigation may require expertise in the claimed technology. Product liability cases may call for medical, pharmacological, engineering, or epidemiological analysis. FCA matters can require reimbursement, statistical, or compliance expertise.
Expert analysis must remain consistent with discovery, technical records, regulatory documents, and the company's litigation position.
Motions, Trial, and Settlement
Claim construction, patent-validity issues, expert challenges, jurisdictional motions, summary judgment, agency developments, or targeted discovery can materially narrow the dispute before trial.
Settlement analysis may also turn on patent exclusivity, licensing rights, product sales, regulatory consequences, confidentiality, future business relationships, and parallel investigations rather than damages alone.
5. Frequently Asked Questions about Life Sciences Litigation
Scientific evidence, regulatory history, expert testimony, and the product's development lifecycle often determine issues that would not arise in an ordinary business dispute. The same case may require patent, contract, regulatory, scientific, and commercial analysis at different stages.
A complaint, subpoena, investigation notice, patent assertion, product liability claim, demand letter, or failed collaboration can create immediate litigation issues. Earlier review is particularly important when evidence is at risk, injunctive relief is possible, or government activity is moving in parallel.
The forum depends on the claim. Patent litigation arises under federal law, and False Claims Act matters involve a federal statutory framework. Contract and product liability disputes often arise under state law, although federal jurisdiction may exist. Trade secret claims may proceed under the federal Defend Trade Secrets Act, state law, or both.
6. Speak with a Life Sciences Attorney about a Business Dispute
A subpoena, patent assertion, product claim, investigation notice, or failed collaboration can create several legal problems at once. The first review should determine which dispute controls, what records are at risk, and whether regulatory or government proceedings are moving in parallel.
For a pharmaceutical, biotechnology, medical device, diagnostics, or laboratory company, the practical consequences may extend beyond the lawsuit itself. Product development, intellectual property, commercialization rights, regulatory activity, and ongoing business relationships can all be affected by the litigation position.
The initial record should include the operative agreements, key technical or scientific files, regulatory correspondence, litigation or investigation notices, relevant deadlines, and the identities of employees who understand the disputed events. That record provides the basis for deciding whether the next step is emergency relief, targeted discovery, motion practice, negotiation, or trial.
28 Sep, 2026
